Fraunhoferstraße 22
Planegg 82152
Germany
49 89 700 763 0
https://www.4sc.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 13
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Jason Loveridge B.Sc., FRSM, Ph.D. | Chairman of Management Board, CEO & MD | 519k | S.O. | S.O. |
Ms. Kathleen Masch-Wiest | COO & Member of the Management Board | S.O. | S.O. | S.O. |
Ms. Anna Niedl Ph.D. | Corporate Communications & Investor Relations Officer | S.O. | S.O. | S.O. |
Dr. Susanne Danhauser-Riedl M.D. | Chief Medical Officer | S.O. | S.O. | S.O. |
Ms. Larissa Stuttem | Team Assistant | S.O. | S.O. | S.O. |
4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany. Its product Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma, which is in clinical development stage. The company also out-licenses its products to pharma and biotech companies. The company was founded in 1997 and is headquartered in Planegg, Germany.
L’ISS Governance QualityScore de 4SC AG en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..